Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + trabectedin
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Bevacizumab + trabectedin is a combination of two anticancer agents used in clinical trials for the treatment of certain cancers, including ovarian cancer and soft tissue sarcoma. Bevacizumab is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), thereby blocking angiogenesis and reducing tumor blood supply. Trabectedin is an alkylating agent that binds to the minor groove of DNA, causing DNA damage, cell cycle arrest, and apoptosis in cancer cells. Additionally, trabectedin modulates the tumor microenvironment by affecting tumor-associated macrophages and vascular endothelial cells. The combination aims to leverage both direct cytotoxic effects on tumors (trabectedin) and antiangiogenic activity (bevacizumab) for synergistic antitumor efficacy[1][2][3][5][6].
- Brand names
- Vegzalma
- Other names
- none
02
Targets
Beyond the preview
Go deeper on bevacizumab + trabectedin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + trabectedin.